Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
Proposed Pilot Study of Combined Optune+ Bevacizumab, and Hypofractionated Stereotactic Irradiation for Bevacizumab-Naive Recurrent Glioblastoma
Sponsor: NovoCure Ltd.
Terminated
Poor accrual
Other terminated trials from NovoCure Ltd.
- Extensive Stage Lung Small Cell Carcinoma · Phase PHASE2 · Aug 2022
- Brain Tumor · Phase PHASE1 · Feb 2022
- Melanoma With Brain Metastasis · Phase PHASE2 · Nov 2021
- GBM · Phase PHASE2 · Jun 2021
- Brain Neoplasms · Phase NA · May 2021
More terminations from NovoCure Ltd.
Listed as NCT01925573, this NA trial focuses on Brain Tumor and RECURRENT GLIOBLASTOMA and remains terminated or withdrawn. Sponsored by NovoCure Ltd., it has been updated 10 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Mar 2022 — Jul 2024 [monthly]
Terminated NA
-
Jan 2021 — Mar 2022 [monthly]
Terminated NA
-
Dec 2020 — Jan 2021 [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
▶ Show 5 earlier versions
-
Sep 2019 — Dec 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Sep 2019 [monthly]
Recruiting NA
-
Aug 2018 — Aug 2019 [monthly]
Recruiting NA
-
Jun 2018 — Aug 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NovoCure Ltd.
- University of Maryland, Baltimore
For direct contact, visit the study record on ClinicalTrials.gov .